Gain Therapeutics (GANX) Other Accumulated Expenses (2020 - 2026)

Gain Therapeutics' Other Accumulated Expenses history runs 7 years deep, the most recent figure standing at $287469.0 for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 29.31% year-over-year to $287469.0; the TTM figure through Mar 2026 stood at $287469.0 (up 29.31% YoY), while the FY2025 annual figure was $13645.0, up 30.99% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $287469.0, up from $13645.0 in the prior quarter.
• The five-year high for Other Accumulated Expenses was $3.5 million in Q2 2024, with the low at $10417.0 in Q4 2024.
• The 5-year median for Other Accumulated Expenses is $2.2 million (2023), against an average of $1.8 million.
• The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses sank 99.52% in 2024, then jumped 799.03% in 2025.
• Gain Therapeutics' Other Accumulated Expenses stood at $2.1 million in 2022, then grew by 2.54% to $2.2 million in 2023, then tumbled by 99.52% to $10417.0 in 2024, then soared by 30.99% to $13645.0 in 2025, then soared by 2006.77% to $287469.0 in 2026.
• Business Quant data shows GANX's Other Accumulated Expenses at $287469.0 in Q1 2026, $13645.0 in Q4 2025, and $2.3 million in Q3 2025.